Surgery is the only potentially curative treatment. Yet, despite that, nearly 90% of patients who are able to undergo it have disease recurrence at a median of 7-9 months. Even with the addition of multi-agent adjuvant chemotherapies, nearly 80% of patients have disease recurrence at around 14 months.
In the trial, the vaccine was given as an adjuvant therapy, along with a modified version of FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin), and an anti-PD-L1.
In half of the patients the separation of the curves is incredible.
News 
Market Data 
Discover 
